UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 4.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 844,345 shares of the biotechnology company's stock after purchasing an additional 33,804 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.30% of Exelixis worth $28,117,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Coppell Advisory Solutions LLC bought a new position in shares of Exelixis during the 4th quarter worth approximately $25,000. Colonial Trust Co SC lifted its position in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after buying an additional 765 shares during the period. Principal Securities Inc. lifted its position in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after buying an additional 373 shares during the period. Kestra Investment Management LLC bought a new position in shares of Exelixis during the 4th quarter worth approximately $39,000. Finally, Crowley Wealth Management Inc. bought a new position in shares of Exelixis during the 4th quarter worth approximately $50,000. Institutional investors and hedge funds own 85.27% of the company's stock.
Insider Buying and Selling
In other Exelixis news, Director Tomas J. Heyman sold 4,544 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $44.29, for a total value of $201,253.76. Following the completion of the transaction, the director now directly owns 32,470 shares of the company's stock, valued at approximately $1,438,096.30. The trade was a 12.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Dana Aftab sold 1,508 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $39.00, for a total value of $58,812.00. Following the completion of the transaction, the executive vice president now directly owns 693,181 shares of the company's stock, valued at approximately $27,034,059. The trade was a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 441,740 shares of company stock valued at $20,282,998 over the last three months. Company insiders own 2.82% of the company's stock.
Exelixis Price Performance
Shares of NASDAQ EXEL traded up $0.21 during midday trading on Friday, hitting $42.81. The stock had a trading volume of 3,886,221 shares, compared to its average volume of 2,317,839. Exelixis, Inc. has a fifty-two week low of $21.36 and a fifty-two week high of $48.85. The company's 50-day simple moving average is $38.45 and its 200 day simple moving average is $36.38. The firm has a market cap of $11.67 billion, a P/E ratio of 24.19, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25.
Wall Street Analyst Weigh In
Several equities analysts recently commented on EXEL shares. Guggenheim set a $45.00 target price on Exelixis and gave the stock a "buy" rating in a research report on Thursday, May 15th. Morgan Stanley restated an "overweight" rating and set a $47.00 target price (up previously from $40.00) on shares of Exelixis in a research report on Wednesday, May 14th. Piper Sandler lifted their price objective on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. JMP Securities reiterated a "market outperform" rating and issued a $41.00 price objective on shares of Exelixis in a research report on Thursday, April 17th. Finally, Wells Fargo & Company reiterated a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $38.94.
View Our Latest Research Report on EXEL
About Exelixis
(
Free Report)
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
See Also
Before you consider Exelixis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exelixis wasn't on the list.
While Exelixis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
